Biotech Values

[Jonathan Robinson]

MYGN has taken this to the next level and its stock price has done well recently as its testing diagnostics business grows very well. Somewhat controversial charging what it does for some of the breast cancer screening tests which may or may not work that well (something like $4K a pop). This business for them is probably worth the current stock price, making one wonder about other companies' AD valuations.

Jon